NK cells sense tumors, course of disease and treatments: Consequences for NK-based therapies

OncoImmunology

Volumn 1, Issue 1, 2012, Pages 38-47

  Fregni, Giulia ^a   Perier, Aurélie ^a   Avril, Marie Françoise ^a,b   Caignard, Anne ^a  

^a INSTITUT COCHIN   (France)

^b Hôpital Cochin ^*  (France)

Author keywords

Chemotherapy; NK cells; Tumors

Indexed keywords

IMATINIB; SORAFENIB; SUNITINIB;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER CELL; CELL INFILTRATION; CELL THERAPY; CELLULAR IMMUNITY; CIRCULATING TUMOR CELL; DISEASE COURSE; GASTROINTESTINAL STROMAL TUMOR; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOGENICITY; KIDNEY CARCINOMA; MELANOMA; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 84883358274     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.1.1.18312     Document Type: Review

References (79)

1. Herberman RB, Nunn ME, Holden HT, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer 1975; 16: 230-9; http://dx.doi.org/10.1002/ijc.2910160205.
2. Kiessling R, Klein E, Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 1975; 5:112-7; http://dx.doi.org/10.1002/eji.1830050208.
3. Velardi A, Ruggeri L, Mancusi A, Aversa F, Christiansen FT. Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia. Curr Opin Immunol 2009; 21:525-30; http://dx.doi.org/10.1016/j.coi.2009.07.015.
4. Velardi A, Ruggeri L, Mancusi A, Burchielli E, Perruccio K, Aversa F, et al. Clinical impact of natural killer cell reconstitution after allogeneic hematopoietic transplantation. Semin Immunopathol 2008; 30:489-503; http://dx.doi.org/10.1007/s00281-008-0136-1.
5. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:2097-100; http://dx.doi.org/10.1126/science.1068440.
6. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000; 356:1795-9; http://dx.doi.org/10.1016/S0140-6736(00)03231-1.
7. Levy EM, Roberti MP, Mordoh J. Natural killer cells in human cancer: from biological functions to clinical applications. J Biomed Biotechnol 2011; 2011:676198; http://dx.doi.org/10.1155/2011/ 676198.
8. Ljunggren HG, Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 2007; 7:329-39; http://dx.doi.org/10.1038/nri2073.
9. Haynes NM, van der Most RG, Lake RA, Smyth MJ. Immunogenic anti-cancer chemotherapy as an emerging concept. Curr Opin Immunol 2008; 20:545-57; http://dx.doi.org/10.1016/j.coi.2008.05.008.
10. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8:59-73; http://dx.doi.org/10.1038/nri2216.
11. George DJ, Kaelin WG, Jr. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med 2003; 349:419-21; 12890838; http://dx.doi.org/10.1056/NEJMp030061.
12. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994; 7:85-90; http://dx.doi.org/10.1038/ng0594-85.
13. Gati A, Da Rocha S, Guerra N, Escudier B, Moretta A, Chouaib S, et al. Analysis of the natural killer mediated immune response in metastatic renal cell carcinoma patients. Int J Cancer 2004; 109:393-401; 14961578; http://dx.doi.org/10.1002/ijc.11730.
14. Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy JP, Jr., Takahashi Y, et al. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulinlike receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 2004; 104:170-7; http://dx.doi.org/10.1182/blood-2003-12-4438.
15. Schleypen JS, Von Geldern M, Weiss EH, Kotzias N, Rohrmann K, Schendel DJ, et al. Renal cell carcinomainfiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes. Int J Cancer 2003; 106:905-12; http://dx.doi.org/10.1002/ijc.11321.
16. Perier A, Fregni G, Wittnebel S, Gad S, Allard M, Gervois N, et al. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma. Oncogene 2011; 30:2622-32; http://dx.doi.org/10. 1038/onc.2010.638.
17. Ivanov SV, Salnikow K, Ivanova AV, Bai L, Lerman MI. Hypoxic repression of STAT1 and its downstream genes by a pVHL/HIF-1 target DEC1/STRA13. Oncogene 2007; 26:802-12; http://dx.doi.org/10.1038/sj.onc.1209842.
18. Gobin SJ, van den Elsen PJ. Transcriptional regulation of the MHC class Ib genes HLA-E, HLA-F, and HLA-G. Hum Immunol 2000; 61:1102-7; 11137213; http://dx.doi.org/10.1016/S0198-8859(00) 00198-1.
19. Aptsiauri N, Cabrera T, Mendez R, Garcia-Lora A, Ruiz-Cabello F, Garrido F. Role of altered expression of HLA class I molecules in cancer progression. Adv Exp Med Biol 2007; 601:123-31; http://dx.doi.org/10.1007/978-0-387-72005-0_13.
20. Luo L, Lu J, Wei L, Long D, Guo JY, Shan J, et al. The role of HIF-1 in up-regulating MICA expression on human renal proximal tubular epithelial cells during hypoxia/reoxygenation. BMC Cell Biol 2010; 11:91; http://dx.doi.org/10.1186/1471-2121-11-91.
21. Wei L, Lu J, Feng L, Long D, Shan J, Li S, et al. HIF-1alpha accumulation upregulates MICA and MICB expression on human cardiomyocytes and enhances NK cell cytotoxicity during hypoxia-reoxygenation. Life Sci 2010; 87:111-9; http://dx.doi.org/10.1016/j.lfs.2010.05.012.
22. Baron F, Turhan AG, Giron-Michel J, Azzarone B, Bentires-Alj M, Bours V, et al. Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression. Blood 2002; 99:2107-13; http://dx.doi.org/10.1182/blood.V99.6.2107.
23. Cebo C, Voutsadakis IA, Da Rocha S, Bourhis JH, Jalil A, Azzarone B, Turhan AG, Chelbi-Alix M, Chouaib S, Caignard A. Altered IFNgamma signaling and preserved susceptibility to activated natural killer cellmediated lysis of BCR/ABL targets. Cancer Res 2005; 65:2914-20.
24. Cebo C, Da Rocha S, Wittnebel S, Turhan AG, Abdelali J, Caillat-Zucman S, et al. The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation. J Immunol 2006; 176:864-72.
25. Terme M, Borg C, Guilhot F, Masurier C, Flament C, Wagner EF, et al. BCR/ABL promotes dendritic cellmediated natural killer cell activation. Cancer Res 2005; 65:6409-17; http://dx.doi.org/10.1158/0008-5472.CAN-04-2675.
26. Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 2006; 20:2149-82; http://dx.doi.org/10.1101/gad.1437206.
27. Pierson BA, Miller JS. The role of autologous natural killer cells in chronic myelogenous leukemia. Leuk Lymphoma 1997; 27:387-99.
28. Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, Reviron D, et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 2002; 99:3661-7; http://dx.doi.org/10.1182/blood.V99.10.3661.
29. Kiladjian JJ, Bourgeois E, Lobe I, Braun T, Visentin G, Bourhis JH, et al. Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. Leukemia 2006; 20:463-70; 16408099; http://dx.doi.org/10.1038/sj.leu.2404080.
30. Garcia-Iglesias T, Del Toro-Arreola A, Albarran-Somoza B, Del Toro-Arreola S, Sanchez-Hernandez PE, Ramirez-Duenas MG, et al. Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC Cancer 2009; 9:186; http://dx.doi.org/10.1186/1471-2407-9-186.
31. Fregni G, Perier A, Pittari G, Jacobelli S, Sastre X, Gervois N, et al. Unique Functional Status of Natural Killer Cells in Metastatic Stage IV Melanoma Patients and Its Modulation by Chemotherapy. Clin Cancer Res 2011; 17:2628-37; http://dx.doi.org/10.1158/1078-0432.CCR-10-2084.
32. Konjević G, Mirjacic Martinovic K, Vuletic A, Jovic V, Jurisic V, Babovic N, et al. Low expression of CD161 and NKG2D activating NK receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients. Clin Exp Metastasis 2007; 24:1-11; 17295095; http://dx.doi.org/10.1007/s10585-006-9043-9.
33. Markel G, Seidman R, Besser MJ, Zabari N, Ortenberg R, Shapira R, et al. Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cells. PLoS ONE 2009; 4:e5597; http://dx.doi.org/10.1371/journal.pone.0005597.
34. Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest 2011; 121:3609-22; http://dx.doi.org/10.1172/JCI45816.
35. Schleypen JS, Baur N, Kammerer R, Nelson PJ, Rohrmann K, Grone EF, et al. Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res 2006; 12:718-25; http://dx.doi.org/10.1158/1078-0432.CCR-05-0857.
36. Wittnebel S, Da Rocha S, Giron-Michel J, Jalil A, Opolon P, Escudier B, et al. Membrane-bound interleukin (IL)-15 on renal tumor cells rescues natural killer cells from IL-2 starvation-induced apoptosis. Cancer Res 2007; 67:5594-9; http://dx.doi.org/10.1158/0008-5472.CAN-06-4406.
37. Kornstein MJ, Stewart R, Elder DE. Natural killer cells in the host response to melanoma. Cancer Res 1987; 47:1411-2.
38. Carrega P, Morandi B, Costa R, Frumento G, Forte G, Altavilla G, et al. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer 2008; 112:863-75; 18203207; http://dx.doi.org/10.1002/cncr.23239.
39. Platonova S, Cherfils-Vicini J, Damotte D, Crozet L, Vieillard V, Validire P, et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 2011; 71:5412-22; http://dx.doi.org/10.1158/0008-5472.CAN-10-4179.
40. Delahaye NF, Rusakiewicz S, Martins I, Menard C, Roux S, Lyonnet L, et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med 2011; 17:700-7; http://dx.doi.org/10.1038/nm.2366.
41. Halama N, Braun M, Kahlert C, Spille A, Quack C, Rahbari N, et al. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res 2011; 17:678-89; http://dx.doi.org/10.1158/1078-0432.CCR-10-2173.
42. Takanami I, Takeuchi K, Giga M. The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma. J Thorac Cardiovasc Surg 2001; 121:1058-63; http://dx.doi.org/10.1067/mtc.2001.113026.
43. Villegas FR, Coca S, Villarrubia VG, Jimenez R, Chillon MJ, Jareno J, et al. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 2002; 35:23-8; http://dx.doi.org/10.1016/S0169-5002(01)00292-6.
44. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, et al. prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 2000; 88:577-83; http://dx.doi.org/10.1002/(SICI)1097-0142(20000201)88:3,577::AIDCNCR13.3 .0.CO;2-V.
45. Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 1997; 79:2320-8; 9191519; http://dx.doi.org/10.1002/(SICI)1097-0142(19970615)79:12,2320::AID-CNCR5 .3.0.CO;2-P.
46. Gannon PO, Poisson AO, Delvoye N, Lapointe R, Mes-Masson AM, Saad F. Characterization of the intraprostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods 2009; 348:9-17; http://dx.doi.org/10.1016/j.jim.2009.06.004.
47. McKay K, Moore PC, Smoller BR, Hiatt KM. Association between natural killer cells and regression in melanocytic lesions. Hum Pathol 2011; http://dx.doi.org/10.1016/j.humpath.2011.02.019.
48. Esendagli G, Bruderek K, Goldmann T, Busche A, Branscheid D, Vollmer E, et al. Malignant and nonmalignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer. Lung Cancer 2008; 59:32-40; 17825949; http://dx.doi.org/10.1016/j.lungcan.2007.07.022.
49. Freud AG, Becknell B, Roychowdhury S, Mao HC, Ferketich AK, Nuovo GJ, et al. A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity 2005; 22: 295-304; http://dx.doi.org/10.1016/j.immuni.2005.01.013.
50. Carlsten M, Norell H, Bryceson YT, Poschke I, Schedvins K, Ljunggren HG, et al. Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J Immunol 2009; 183:4921-30; http://dx.doi.org/10.4049/jimmunol.0901226.
51. Blümke K, Bilkenroth U, Schmidt U, Melchior A, Fussel S, Bartel F, et al. Detection of circulating tumor cells from renal carcinoma patients: experiences of a two-center study. Oncol Rep 2005; 14:895-9.
52. Rao C, Bui T, Connelly M, Doyle G, Karydis I, Middleton MR, et al. Circulating melanoma cells and survival in metastatic melanoma. Int J Oncol 2011; 38:755-60.
53. Sanislo L, Vertakova-Krakovska B, Kuliffay P, Brtko J, Galbava A, Galbavy S. Detection of circulating tumor cells in metastatic breast cancer patients. Endocr Regul 2011; 45:113-24; http://dx.doi.org/10.4149/endo_2011_03_113.
54. Sergeant G, Penninckx F, Topal B. Quantitative RTPCR detection of colorectal tumor cells in peripheral blood-a systematic review. J Surg Res 2008; 150:144-52; http://dx.doi.org/10.1016/j.jss.2008.02.012.
55. Grégoire C, Chasson L, Luci C, Tomasello E, Geissmann F, Vivier E, et al. The trafficking of natural killer cells. Immunol Rev 2007; 220:169-82; 17979846; http://dx.doi.org/10.1111/j.1600-065X. 2007.00563.x.
56. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419:734-8; http://dx.doi.org/10.1038/nature01112.
57. Raffaghello L, Prigione I, Airoldi I, Camoriano M, Levreri I, Gambini C, et al. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 2004; 6:558-68; http://dx.doi.org/10.1593/neo.04316.
58. Dunker K, Schlaf G, Bukur J, Altermann WW, Handke D, Seliger B. Expression and regulation of non-classical HLA-G in renal cell carcinoma. Tissue Antigens 2008; 72:137-48; http://dx.doi.org/10.1111/j.1399-0039.2008.01090.x.
59. Ibrahim EC, Guerra N, Lacombe MJ, Angevin E, Chouaib S, Carosella ED, et al. Tumor-specific upregulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Res 2001; 61:6838-45.
60. Lesport E, Baudhuin J, LeMaoult J, Sousa S, Doliger C, Carosella ED, et al. Human melanoma cell secreting human leukocyte antigen-G5 inhibit natural killer cell cytotoxicity by impairing lytic granules polarization toward target cell. Hum Immunol 2009; 70:1000-5; http://dx.doi.org/10.1016/j.humimm. 2009.07.019.
61. Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Le Gal FA, et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA 1998; 95:4510-5; http://dx.doi.org/10.1073/pnas.95.8.4510.
62. LeMaoult J, Zafaranloo K, Le Danff C, Carosella ED. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J 2005; 19:662-4.
63. Campoli M, Ferrone S. Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands. Tissue Antigens 2008; 72:321-34; http://dx.doi.org/10.1111/j.1399-0039.2008.01106.x.
64. Allard M, Oger R, Vignard V, Percier JM, Fregni G, Perier A, et al. Serum Soluble HLA-E in Melanoma: A New Potential Immune-Related Marker in Cancer. PLoS ONE 2011; 6:e21118; http://dx.doi.org/10.1371/journal.pone.0021118.
65. Budagian V, Bulanova E, Paus R, Bulfone-Paus S. IL-15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev 2006; 17:259-80; http://dx.doi.org/10.1016/j.cytogfr.2006.05.001.
66. Budagian V, Bulanova E, Orinska Z, Pohl T, Borden EC, Silverman R, et al. Reverse signaling through membrane-bound interleukin-15. J Biol Chem 2004; 279:42192-201; http://dx.doi.org/10.1074/jbc.M403182200.
67. Khawam K, Giron-Michel J, Gu Y, Perier A, Giuliani M, Caignard A, et al. Human renal cancer cells express a novel membrane-bound interleukin-15 that induces, in response to the soluble interleukin-15 receptor alpha chain, epithelial-to-mesenchymal transition. Cancer Res 2009; 69:1561-9; http://dx.doi.org/10.1158/0008-5472.CAN-08-3198.
68. Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, Conte R, et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA 2003; 100:4120-5; http://dx.doi.org/10.1073/pnas.0730640100.
69. Hagemann T, Bozanovic T, Hooper S, Ljubic A, Slettenaar VI, Wilson JL, et al. Molecular profiling of cervical cancer progression. Br J Cancer 2007; 96:321-8; http://dx.doi.org/10.1038/sj.bjc.6603543.
70. Mansfield AS, Holtan SG, Grotz TE, Allred JB, Jakub JW, Erickson LA, et al. Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis. Mod Pathol 2011; 24:487-94; 21151098; http://dx.doi.org/10.1038/modpathol.2010.227.
71. Balsamo M, Scordamaglia F, Pietra G, Manzini C, Cantoni C, Boitano M, et al. Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc Natl Acad Sci USA 2009; 106: 20847-52; http://dx.doi.org/10.1073/pnas.0906481106.
72. Nardin A, Wong WC, Tow C, Molina TJ, Tissier F, Audebourg A, et al. Dacarbazine promotes stromal remodeling and lymphocyte infiltration in cutaneous melanoma lesions. J Invest Dermatol 2011; 131:1896-905; http://dx.doi.org/10.1038/jid.2011.128.
73. Krusch M, Salih J, Schlicke M, Baessler T, Kampa KM, Mayer F, et al. The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro. J Immunol 2009; 183:8286-94; http://dx.doi.org/10.4049/jimmunol.0902404.
74. Borg C, Terme M, Taieb J, Menard C, Flament C, Robert C, et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 2004; 114:379-88.
75. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005; 436: 1186-90; http://dx.doi.org/10.1038/nature03884.
76. Beano A, Signorino E, Evangelista A, Brusa D, Mistrangelo M, Polimeni MA, et al. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J Transl Med 2008; 6:25; http://dx.doi.org/10.1186/1479-5876-6-25.
77. Bonilla F, Alvarez-Mon M, Merino F, Giron JA, Menendez JL, Espana P, et al. Natural killer activity in patients with breast cancer. Eur J Gynaecol Oncol 1990; 11:103-9.
78. Mozaffari F, Lindemalm C, Choudhury A, Granstam-Bjorneklett H, Helander I, Lekander M, et al. NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy. Br J Cancer 2007; 97:105-11; 17551492; http://dx.doi.org/10.1038/sj.bjc.6603840.
79. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105:3051-7; http://dx.doi.org/10.1182/blood-2004-07-2974.